Literature DB >> 27873609

Carbapenemases: Partners in crime.

Karen Bush1.   

Abstract

Carbapenemases, β-lactamases that inactivate carbapenems and most β-lactam antibiotics, are most widely known for their ability to confer resistance to β-lactams. They include serine carbapenemases, such as the widespread KPC family of enzymes, and the metallo-β-lactamases that contain the IMP, NDM and VIM enzyme families acquired by Gram-negative bacteria on transferable elements. These enzymes are almost always produced by organisms that encode at least one other β-lactamase, with as many as eight different β-lactamase genes detected in a single isolate. This consortium of β-lactamases includes a full spectrum of molecular and biochemical characteristics, providing the producing organism with a range of catalytic activities. In addition to the variety of β-lactamases found in carbapenemase-producing Gram-negative pathogens are multiple other resistance factors, especially aminoglycoside-modifying enzymes and 16S rRNA methylases that confer resistance to aminoglycosides. Other acquired genes encode fluoroquinolone, trimethoprim, sulfonamide, rifampicin and chloramphenicol resistance determinants on mobile elements that travel together with β-lactamase genes. Thus, the recent proliferation of transferable carbapenemases serves to magnify resistance to virtually all antibiotic classes. Judicial use of current antibiotics and a quest for novel antibacterial agents are necessary, as multidrug-resistant bacteria continue to multiply. Copyright Â
© 2013 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenemase; Metallo-β-lactamase; Resistance; β-Lactamase

Year:  2013        PMID: 27873609     DOI: 10.1016/j.jgar.2013.01.005

Source DB:  PubMed          Journal:  J Glob Antimicrob Resist        ISSN: 2213-7165            Impact factor:   4.035


  26 in total

1.  Evaluation of the Immunochromatographic NG-Test Carba 5 for Rapid Identification of Carbapenemase in Nonfermenters.

Authors:  Anaïs Potron; Damien Fournier; Cécile Emeraud; Pauline Triponney; Patrick Plésiat; Thierry Naas; Laurent Dortet
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

2.  X-ray Crystallography Deciphers the Activity of Broad-Spectrum Boronic Acid β-Lactamase Inhibitors.

Authors:  Laura Cendron; Antonio Quotadamo; Lorenzo Maso; Pierangelo Bellio; Martina Montanari; Giuseppe Celenza; Alberto Venturelli; Maria Paola Costi; Donatella Tondi
Journal:  ACS Med Chem Lett       Date:  2019-03-27       Impact factor: 4.345

3.  VIM-2-Producing Pseudomonas spp. in Uruguay: Sequence Types, Pulsotypes, and Class 1 Integrons Including New Variable Regions Featuring blaVIM-2 and blaGES-7.

Authors:  Romina Papa Ezdra; Inés Bado; Nicolás Cordeiro; Claudia Gutierrez; Patricia Hitateguy; Verónica Seija; Rafael Vignoli
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

Review 4.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

5.  In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).

Authors:  Boudewijn L M de Jonge; James A Karlowsky; Krystyna M Kazmierczak; Douglas J Biedenbach; Daniel F Sahm; Wright W Nichols
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 6.  Past and Present Perspectives on β-Lactamases.

Authors:  Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

Review 7.  Epidemiology of β-Lactamase-Producing Pathogens.

Authors:  Karen Bush; Patricia A Bradford
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

8.  Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.

Authors:  David van Duin; Cesar A Arias; Lauren Komarow; Liang Chen; Blake M Hanson; Gregory Weston; Eric Cober; Omai B Garner; Jesse T Jacob; Michael J Satlin; Bettina C Fries; Julia Garcia-Diaz; Yohei Doi; Sorabh Dhar; Keith S Kaye; Michelle Earley; Andrea M Hujer; Kristine M Hujer; T Nicholas Domitrovic; William C Shropshire; An Dinh; Claudia Manca; Courtney L Luterbach; Minggui Wang; David L Paterson; Ritu Banerjee; Robin Patel; Scott Evans; Carol Hill; Rebekka Arias; Henry F Chambers; Vance G Fowler; Barry N Kreiswirth; Robert A Bonomo
Journal:  Lancet Infect Dis       Date:  2020-03-06       Impact factor: 25.071

9.  Role of Residues W228 and Y233 in the Structure and Activity of Metallo-β-Lactamase GIM-1.

Authors:  Susann Skagseth; Trine Josefine Carlsen; Gro Elin Kjæreng Bjerga; James Spencer; Ørjan Samuelsen; Hanna-Kirsti S Leiros
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

Review 10.  Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase Inhibitors.

Authors:  Anou M Somboro; John Osei Sekyere; Daniel G Amoako; Sabiha Y Essack; Linda A Bester
Journal:  Appl Environ Microbiol       Date:  2018-08-31       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.